Despite remarkable progress in diagnosis and treatment, malignant glioma, a highly lethal cancer of the central nervous system, remains incurable. Although glioma stem-like cells (GSCs) represent a relatively small fraction of the cells in malignant glioma, they can proliferate and self renew extensively, being crucial for tumor recurrence. Cancer treatment by sonodynamic therapy (SDT) chiefly depends on antitumor effects of reactive oxygen species (ROS) generated from a sonosensitizer activated by ultrasound. Although SDT effectively kills glioma cells, its efficiency against GSCs is not established. We attempted to compare the susceptibility of GSCs to SDT, using Photofrin, a porphyrin-derivative photosensitizer, with that of glioma cells. Cell viability and apoptosis assays showed that SDT damaged both GSCs and U251 glioma cells, but GSCs were significantly less susceptible to SDT (p , 0.01). To elucidate the mechanism of the antitumor effects of SDT, we evaluated intracellular ROS production and Photofrin uptake: ROS production and Photofrin content were significantly lower (p , 0.01) in GSCs than in U251 glioma cells. Thus, cellular differences in sonosensitizer uptake and ROS production influence the antitumor effects of SDT. Furthermore, the resistance of GSCs may be caused by decreased sonosensitizer uptake due to ABCG2 overexpression.
Introduction
Malignant glioma, classified as World Health Organization grade-IV, is the most common and biologically aggressive primary CNS tumor, annually accounting for 22-27% of all primary brain tumors. Despite advances in diagnosis and therapy, average survival after diagnosis is only 12-18 months (1). Tumors recur due to further infiltration by cancer cells that remain even after successful tumor resection. Malignant glioma contains a small subset of self-renewing tumor cells, glioma cancer-like stem cells (GSCs), which aggressively migrate (2, 3). The success of any therapeutic modality depends on eradicating the remaining GSCs after surgical resection.
Sonodynamic therapy (SDT), a noninvasive modality for cancer treatment, is based on the systemic administration and local accumulation of a sonosensitizer Technology in Cancer Research & Treatment, Volume 11, Number 6, December 2012 (e.g., porphyrin or its derivatives) and its subsequent activation by ultrasound in tumor tissues. The sonosensitizer generates singlet oxygen and other ROS, which kill cancer cells directly by inducing apoptotic and non-apoptotic cell death pathways (4, 5) . Although SDT can effectively kill glioma cells (6, 7), GSCs and glioma cells appear to have different biological and molecular characteristics (8, 9) .
Photofrin, a derivative of porphyrin, is approved by the United States Food and Drug Administration and is widely used for treatment of various cancers in clinical photodynamic therapy (PDT) (10, 11) . Used as a sonosensitizer for SDT, Photofrin has been shown to effectively kill various cancer cells, including glioma cells (12) (13) (14) .
Cells overexpressing ABCG2, a member of the ATP-binding cassette transporter family (15, 16) , can pump endogenous and exogenous porphyrin-based compounds, including Photofrin, out of cells, decreasing the efficacy of PDT (17, 18) .
We investigated whether GSCs have similar susceptibility as glioma cells to SDT with Photofrin in vitro, and explored the mechanism of the antitumor effects of SDT in terms of intracellular sonosensitizer uptake and ROS production. We also analyzed ABCG2 expression on GSCs.
Materials and Methods

Reagents and Antibodies
Dulbecco's modified Eagle's medium with Ham's F-12 medium supplements (DMEM/F12), fetal calf serum (FCS), N2, B27, Photofrin, 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA), and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were obtained from Sigma-Aldrich (St. Louis, MO). Recombinant human epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), and leukemia inhibitory growth factor (LIF) were purchased from PeproTech (Rocky Hill, NJ). Rabbit polyclonal antihuman nestin, GFAP, glial fibrillary acidic protein (GFAP) and NF-200, mouse monoclonal anti-human CD133 and 2′,3′-cyclic nucleotide 3′-phosphodiesterase (CNPase), and fluorescent secondary antibody, were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). The fluorescein TdT-UTP nick end labeling (TUNEL) apoptosis assay kit was obtained from the Beyotime Institute of Biotechnology (Haimen, Jiangsu Province, China).
Cell Preparation
U251 glioma cells (Beijing Institute of Biology, Chinese Academy of Science) were cultured in DMEM/F12 containing 10% FCS, with medium change every 3-4 days and passaging every 7 days.
To isolate GSCs, U251 glioma single-cell suspensions (1 3 10 6 cells/mL) were cultured in serum-free DMEM/F12 medium containing 1% N2, 2% B27, 10 ng/mL EGF, 10 ng/mL bFGF, and 10 ng/mL LIF at 37C, 5.0% CO 2 , and 100% humidity. The medium was changed every 3-4 days, and cells were passaged 5 times with trypsinization every 7 days, before experimentation.
Immunocytochemistry
For stemness analysis, neurospheres derived from U251 glioma cells were plated onto laminin-coated coverslips and cultured for 12 h in serum-free medium. After fixation with 4% paraformaldehyde for 15 min, the coverslips were washed thrice with PBS and permeabilized with 0.1% Triton X-100 for 10 min. They were then washed with PBS and incubated with blocking buffer (3% BSA and 3% horse serum in PBS) for 2 h. Thereafter, coverslips were incubated with anti-human nestin (1:1000) or anti-human CD133 (1:100), overnight at 4C. Coverslips were washed thrice with PBS and incubated with fluorescent secondary antibody (1:250), for 1 h at room temperature (RT). Finally, the cells were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) and observed by confocal microscopy (Leica, Germany).
For differentiation analysis, single-cell suspensions were plated onto laminin-coated coverslips; cultured for 7 days in DMEM/F12 containing 3% FCS; incubated with anti-human GFAP (1:500), anti-human MAP2 (1:500), and anti-human CNPase (1:200); and observed by confocal microscopy.
Sonosensitizer Uptake Assay
Because Photofrin concentration in cells is a key factor influencing the cellular sensitivity to SDT (14), we analyzed uptake ability of U251 glioma cells and GSCs to determine the best incubation time of Photofrin. U251 glioma cells and GSCs were incubation with 20 μg/mL Photofrin (treatment group) or 0 μg/mL Photofrin (control group) for different time (2 h, 4 h, 6 h, 12 h), and were centrifuged; the resultant pellet resuspended in 2 mL fresh PBS, 2 mL 2% SDS, and 0.2 N NaOH; and heated for 5 min in boiling water (19) . Excitation (403 nm) and emission (625 nm) of the cell extracts were then determined spectrophotometrically. Fluorescence intensities were converted to absolute Photofrin concentrations using standard curves generated from known cellular concentrations of Photofrin.
Experimental Treatments
Single-cell suspensions of U251 glioma cells and GSCs were plated onto laminin-coated 6-well plates at 1.0 3 10 6 cells/mL. After 12-h culture, both cell types were randomly subdivided into 4 groups: control (no treatment), Photofrin, ultrasound, and SDT groups. The cells in the SDT groups were incubated with 20 μg/mL Photofrin, for 6 h in the dark and then activated by ultrasound at 1.0 MHz and 0.5 W/ cm 2 for 1 min (7). The ultrasound device (CZF-2 Seapostar, Chongqing Haifu Technology Co Ltd, Chongqing, China) with a planar ultrasound transducer (diameter is 3 cm) was used. The bottom of culture plates containing cells were immersed in a tank containing 4C degassed water bath stained with black ink, and the plates were fixed and supported with a clamp. For cell sonication, the transducer was placed 1 cm below the bottom of culture plates to generate ultrasound vertically and upwardly. The volume of medium in the well was 3 ml. The concrete set up of the ultrasound treatment was shown as Figure 1 . The cells in the Photofrin group were treated with 20 μg/mL Photofrin only, for 6 h; those in the ultrasound group were treated with ultrasound alone, at 1.0 MHz and 0.5 W/cm 2 , for 1 min.
MTT Assay
To evaluate cell viability after the treatments, the treated cells in all the groups were seeded at 2 3 10 4 cells/well in 96-well plates and cultured for 12 h, 24 h, 48 h. MTT (500 μg/mL) was added, followed by incubation at 37C for 4 h. After cell lysis, the absorbance was measured at 570 nm using a microplate reader, and the cell survival rate (SR) was determined according to the following formula:
SR 5 (OD value in treated groups/OD value in control) 3 100%
TUNEL Assay
To assess apoptotic cell, cells were cultured for 12 h after treatments, fixed with 4.0% paraformaldehyde for 15 min at 4C, washed thrice with PBS, and permeabilized with 0.1% Triton X-100 for 5 min at RT. This was followed by fluorescein isothiocyanate (FITC) TUNEL staining for 1 h at 37C. After nuclear staining with DAPI, the cells were observed by confocal microscopy. For each experiment, 100 randomly chosen cells were examined for the presence of bright blue nuclei, indicative of apoptotic cells.
ROS Production
The generation of ROS is thought to mediate cell apoptosis in response to SDT with Photofrin. Thus, we analyzed the relative production of ROS with 2′,7′-dichlorofluorescein-diacetate (DCFH-DA; Sigma-Aldrich), which is a cell-permeable nonfluorescent probe that is irreversibly oxidized to a fluorescent product (dichlorofluorescein; DCF) by ROS. 1 3 10 6 treated cells were incubated with 10 μmol/L DCFH-DA for 30 min at 37C in the dark. Cells were analyzed by flow cytometry (Beckton Dickinson FACScan) using excitation and emission wavelengths of 488 and 530 nm, respectively (20). Cell Quest 3.2 (Beckton Dickinson) software was used for data acquisition and analysis. Relative ROS production was expressed as fold increase in cells emitting increased fluorescence of experimental groups compared with that of the appropriate controls.
ABCG2 Expression on GSCs and U251 Glioma Cells
For flow cytometric determination of the percentage of GSCs and U251 glioma cells expressing ABCG2, single-cell suspensions were labeled by incubation with FITC-conjugated anti-ABCG2 antibody (Santa Cruz, USA) at 4C for 30 min. Subsequently, cells were washed with PBS, and 1 3 10 6 cells were analyzed by flow cytometry.
To quantitate ABCG2-expression levels in GSCs and U251 glioma cells, proteins were extracted by lysis in SDS buffer supplemented with fresh protease inhibitors (Sigma). Protein concentrations were determined using a BCA protein assay kit (Pierce); equal amounts of protein (30 μg) were separated by 10% SDS-PAGE. Proteins were transferred to polyvinylidene difluoride membranes, which were then blocked with 3% skim milk in Tris-buffered saline con taining 0.3% Tween-20 (TBST) for 90 min at RT, and then incubated overnight at 4C with anti-ABCG2 antibody (1:1000) or anti-glyceraldehyde-3-phosphate dehydrogenase (anti-GAPDH) antibody (as a reference; 1:5000). Membranes were rinsed and incubated with appropriate peroxidase-conjugated secondary antibodies (1:5000). Blots were visualized by enhanced chemiluminescence (Amersham) according to standard procedures. Relative protein levels were quantitated by densitometry with Quantity One software (Bio-Rad).
Statistical Analysis
Data are represented as the mean 6 SEM of triplicate experiments. Groups were compared using Student's t-test or ANOVA followed by the Newman-Keuls correction for multiple comparisons. Differences were considered significant at p , 0.05. 
Results
Neurosphere Formation
Dissociated U251 glioma cells formed neurospheres when cultured in stem cell medium containing EGF and bFGF. Many neurospheres containing 4-10 cells were observed 3-7 days after seeding, and most contained 100-1000 cells after 2 weeks, which could be passaged multiple times. Single cells derived from these neurospheres by mechanical dissociation again formed large neurospheres within 2 weeks of being placed in fresh stem cell medium containing EGF and bFGF.
Immunofluorescence of the Neurospheres
Under undifferentiated conditions, most cells co-expressed the GSC-markers (CD133 and nestin; Figures 2B-D) . In differentiation medium for 7 days, the cells demonstrated the characteristic morphology and expressed the markers characteristic of neurons (NF-200), astrocytes (GFAP), and oligodendrocytes (CNPase; Figures 2E-G) .
Intracellular Photofrin Uptake
As showed in Figure 3 , there was no significantly difference of intracellular Photofrin concentration between U251 glioma cells and GSCs when incubated for 2 h. Since 4 h incubation, Photofrin concentration in U251 glioma cells (0.73 6 0.08 μg/10 6 cells) were always obviously higher (p , 0.01) than GSCs (0.33 6 0.08 μg/10 6 cells). Thus, we concluded Photofrin uptake capacity was significantly different between GSCs and U251 glioma cells, which might be attributed to the drug-efflux ability of GSCs. The highest Photofrin concentration in U251 glioma cells (0.95 6 0.14 μg/10 6 cells) and GSCs (0.35 6 0.07 μg/10 6 cells), were observed after 6 h incubation. After 12 h incubation, Photofrin concentration were slightly decreased in U251 glioma cells and GSCs, this might be explained by the short half-life of Photofrin in cytoplasm. On the basis of these results, we chosed to expose the cells to ultrasound after incubated with 20 μg/mL Photofrin for 6 h in vitro.
Cell Viability
As showed in Figure 4A , Photofrin alone treatment did not significantly affect cell viability, as previously demonstrated (16). Although survival rates were significantly decreased (p , 0.05) at different time points (12 h, 24 h, 48 h) after ultrasonic alone treatment, no significant difference in viability was noted between cell types, respectively, U251 glioma cells: 84.32 6 7.43%, 85.64 6 9.11%, 88.37 6 8.45%, GSCs: 83.45 6 6.11%, 84.06 6 8.67%, 87.63 6 7.33%. The cell survival rates of SDT groups were significantly lower (p , 0.01) than ultrasound groups at different time points. Interestingly, at different time points after SDT, GSCs had significantly better (p , 0.01) survival rates than U251 glioma cells, respectively, GSCs: 43.37 6 4.66%, 45.44 6 6.56%, 52.62 6 5.26%, U251 glioma cells: 20.37 6 3.76%, 21.77 6 5.56%, 27.38 6 4.05%. These results indicated that Photofrin-mediated SDT could significantly decrease cell survival, and GSCs were comparatively resistant as compared to U251 glioma cells to Photofrin-mediated SDT. The lowest survival rates in U251 glioma cells and GSCs were observed at 12 h after SDT, and the survival rates were slightly increased at 48 h, this might be attributed to self repair of reversible damaged tumor cells and proliferation of survival cells. Thus, 12 h after treatment is the best time points to determine the effect of SDT on cells survival in vitro.
Cell Apoptosis
The TUNEL assay demonstrated increased DNA labeling in the fragmented nuclei of SDT cells ( Figures 4C and E) . The proportions of apoptotic cells were not significantly Figure 3 : Comparison of Photofrin uptake. Photofrin content in U251 glioma cells and GSCs were significantly increased after incubated for 2 h, but there was no obviously difference between cell types. Photofrin content in U251 glioma cells and GSCs arrived at the highest level after incubated with Photofrin for 6 h, and Photofrin content in U251 glioma cells was obviously higher than GSCs (p , 0.01). Data represent the mean 6 SEM of triplicate experiments (n 5 8); # p , 0.01, U251 glioma cells versus GSCs. different between the control and the Photofrin groups. Compared to the control cells, ultrasound-treated cells showed significant apoptosis (p , 0.05), but the difference between cell types was not statistically significant (U251 glioma cells: 8.65 6 3.74%; GSCs: 10.15 6 4.57%; Figure 4F ). SDT induced the highest apoptosis rates; in the SDT groups, GSCs had a significantly lower apoptosis rate (p , 0.01) than the U251 glioma cells (63.43 6 8.07% vs. 38.85 6 10.24%; Figure 4F ).
Intracellular ROS Production
The relative ROS production were significantly higher (p , 0.01) in the SDT groups than in the control groups (7.43 6 1.33-fold-increase for U251 glioma cells, and 4.33 6 0.85-fold-increase for GSCs, respectively; Figure  5E ), but not in the Photofrin or ultrasound groups. Further, in the SDT groups, the U251 glioma cells showed significantly higher relative ROS production than the GSCs (7.43 6 1.33-fold-increase vs. 4.33 6 0.85-fold-increase, p , 0.01; Figure 5E ). These results indicated that Photofrin-mediated SDT could produce higher level ROS in U251 glioma cells than in GSCs.
ABCG2 Overexpression in GSCs
Flow cytometry analysis ( Figure 6A ) showed that the average percentage of ABCG2-positive cells in GSCs (93.62 6 11.08%) was significantly higher than in glioma cells (8.64 6 2.32%; p , 0.01). Western blotting showed ABCG2 protein expression was significantly greater in GSCs than in U251 glioma cells ( Figures 5C-D, P , 0.01) .
Discussion
Our findings demonstrate that SDT can effectively decrease survival and induce apoptosis of GSCs derived from U251 glioma cells but that the susceptibility of these GSCs to SDT is considerably less than that of U251 glioma cells. GSCs are considered key in tumorigenesis and tumor recurrence after treatment for malignant glioma; they are suitable targets for designing therapeutic agents and for testing therapeutic efficiency (21).
The GSCs in our experiments met the current standards for GSCs. (a) They generated clusters of clonally derived cells resembling neurospheres during in vitro culture of U251 glioma cells with EGF and bFGF. (b) Cells derived from these neurospheres self-renewed and proliferated. (c) Cells derived from the neurospheres differentiated into neurons, astrocytes, or oligodendrocytes, indicating their multipotency [ Figures 2E-G (2) ].
The antitumor effects of ultrasound alone is predominantly attributed to cavitational; acoustic pressure causes the formation and sudden collapse of microbubbles, which produces shear stress that physically and mechanically causes reversible and irreversible damage to the target cells.
Although previous studies have shown that ultrasound alone can significantly enhance intracellular ROS production (22-24), our ultrasound alone treatment (1.0 MHz and 0.5 W/cm 2 for 1 min) did not significantly enhance ROS production in either cell type; differences in the intensity of sonic energy applied or cellular susceptibility to ultrasound might explain these dissimilar results. The slight difference in the effect of ultrasonic cavitation between U251 glioma cells and GSCs suggests that these cell types have similar susceptibilities to a given intensity of ultrasound alone.
Sonodynamic therapy, a particularly attractive, non-invasive method for treating malignant tumors, is based on the synergistic effects of sonosensitizer and ultrasound used in combination, which induce cell death and tumor ablation. The anti-cancer effects of SDT in vivo and vitro are thought to occur at three different levels. (a) SDT can directly kill tumor cells by apoptosis and/or necrosis when the sonosensitizer has been taken up by tumor cells. (b) SDT can damage the tumor-associated vasculature, which limit blood supply to the region, subsequently lead to tumor death via deprivation of oxygen and nutrients. (c) SDT can stimulate the immune systems to recognize and destroy tumor cells by inducing inflammation at the irradiated site (4, 25, 26). These three factors can also influence each other and synergicly produce anti-cancer effects. Although many biological mechanisms about SDT have been reported, the most general theory is free radical theory. When a sonosensitizer is exposed to ultrasound, it is activated from its ground state into an excited state, and as the activated sonosensitizer returns to the ground state, the energy released can generate reactive oxygen species (ROS), which can destroy the cell membrane, intracellular substances (protein, mitochondrion, and nucleic acid), and even trigger various of apoptotic pathways to promote necrosis and/or apoptosis (22, 27, 28) . As previous studies described, our experiment results also clearly demonstrated that the synergistic effect of ultrasonic activation and intracellular Photofrin accumulation during SDT markedly increased intracellular ROS production, and significantly decreased survival and enhanced apoptosis rates of the tumor cells.
Increasing evidence shows that GSCs derived from glioma cells are phenotypically and functionally different from the parent cells. GSCs are more resistant to chemotherapy and radiotherapy, compared to glioma cells (8, 9) ; similarly, we found that GSCs have stronger resistance to SDT. The production of ROS during SDT depends greatly on sonosensitizer concentration in tumor cells (29-31); therefore, Photofrin uptake by cells may be a crucial factor for the antitumor effect of SDT. Although sensitivity to ultrasound or Photofrin alone were not different between cell types, the synergistic effect of these factors induced significant differences: the ROS production of the U251 glioma cells was significantly higher than that of the GSCs, and correspondingly, the survival rates of the former cell type were lower and the apoptosis rate higher than those of the latter cell type.
Photofrin concentration is believed to play a direct role in ROS production in cells subjected to SDT (29-31). U251 glioma cells had a significantly higher Photofrin content than did GSCs in our study, suggesting that cellular differences in Photofrin uptake affected the antitumor effects of SDT. The difference in Photofrin uptake in this study might be because of the different internal characteristics of U251 glioma cells and GSCs. The principal mechanism of stem cell protection has been demonstrated by the expression of multifunctional efflux transporters from the ATP-binding cassette gene family (32, 33) . ABCG2 is an important multidrug-resistant transporter and has been identified as characteristic of cancer stem cells (15). Our data corresponds to earlier results indicating that CD133 1 glioma cells (GSCs) show significantly higher expression of ABCG2 than CD133 − glioma cells (34, 35) . Moreover, porphyrin and porphyrin derivates have been shown to be substrates of ABCG2. ABCG2 plays a role in maintaining porphyrin homoeostasis, and its overexpression counteracts intracellular increase in endogenous and exogenous porphyrin content (36, 37) . The high affinity of ABCG2 for these molecules is attributed to their tetrapyrrole structure, which facilitates interaction with ABCG2 (38). Therefore, GSCs most likely decrease their intracellular Photofrin concentration through ABCG2, thereby resisting the antitumor effects of SDT.
In summary, SDT has a positive antitumor effect on U251 glioma cells and GSCs, but GSCs are more resistant to SDTinduced cell death. The antitumor effect of SDT is influenced by the intracellular sonosensitizer concentration. We presume that ABCG2 overexpression in GSCs is vital in decreasing intracellular sonosensitizer concentration. In-depth studies into the role of ABCG2 in the transport and elimination of Photofrin could lead to the development of more effective SDT.
